In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Illumina Advances Precision Oncology And Gains Speed In Infectious Disease

Greater Use Of Genomics For Surveillance During COVID-19 Has Shown That Scientists Will No Longer Fight Blind In Infectious Disease Control

Executive Summary

Illumina’s moves into infectious disease testing and further into the clinical setting have been accelerated by the pandemic. The genomic sequencing company is also fast expanding its companion diagnostics oncology partnerships.

You may also be interested in...



JPM 2021: Medtronic, Biogen, Edwards LifeSciences, Guardant Health, Illumina

The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the first day of the meeting.

Illumina Will Pay $8Bn To Buy Back Cancer Screening Start-Up Grail

Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.

Illumina CEO deSouza: Innovation Is ‘Our North Star’

The total addressable market for genomics-based infectious disease testing has expanded in recent months, says Illumina, after becoming the first company to receive a US EUA for a next-generation sequencing-based COVID-19 test. It came amid a raft of innovation activity and tuck-in M&A for the San Diego company.

Topics

Related Companies

UsernamePublicRestriction

Register

IV124721

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel